Skip to main content
Top
Published in: Clinical Rheumatology 8/2013

01-08-2013 | Case Based Review

Exacerbation of latent lupus: is the culprit acid-fast bacilli or antitubercular therapy?

Authors: Harpreet Singh, Sucharita Ray, Maneet Kaur, Vikas Gupta, Harish Kumar, Paulomi Talapatra, Rekha Mathur, Suvrat Arya, Naveen Ghangas

Published in: Clinical Rheumatology | Issue 8/2013

Login to get access

Abstract

Typical as well as atypical presentations of systemic lupus erythematosus are being increasingly recognized due to improved diagnostic methods. In a tuberculosis-endemic country like India, it was traditionally believed that the occurrence of tuberculosis in lupus was due to the chronic immunosuppression caused by lupus or because of the use of steroids or isoniazid-induced lupus. Increasingly several patients with no recorded predisposition to lupus with a history of treatment for tuberculosis are coming with evidence of systemic lupus erythematosus rather than a drug-limited story. Whether the development of an autoimmune state is a mere conjecture or the presence of acid-fast bacilli in the body for a prolonged duration causes complex antigenic interactions leading to an antigenic response needs to be looked into. We present a report of three such patients and review the pathogenetic interactions that could possibly explain the role of mycobacterial antigens as a putative antigen in the pathogenesis of lupus.
Literature
1.
go back to reference Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Aguirre C (2006) High risk of tuberculosis in systemic lupus erythematosus. Lupus 15:232–5CrossRefPubMed Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Aguirre C (2006) High risk of tuberculosis in systemic lupus erythematosus. Lupus 15:232–5CrossRefPubMed
2.
go back to reference Balakrishnan C, Mangat G, Mittal G, Joshi VR (1998) Tuberculosis in patients with systemic lupus erythematosus. J Assoc Physicians India 46:682–3PubMed Balakrishnan C, Mangat G, Mittal G, Joshi VR (1998) Tuberculosis in patients with systemic lupus erythematosus. J Assoc Physicians India 46:682–3PubMed
3.
go back to reference Scadding JG (1960) Mycobacterium tuberculosis in the aetiology of sarcoidosis. Br Med J 2(5213):1617–1623CrossRefPubMed Scadding JG (1960) Mycobacterium tuberculosis in the aetiology of sarcoidosis. Br Med J 2(5213):1617–1623CrossRefPubMed
4.
go back to reference Sayarlioglu M, Inanc M, Kamali S et al (2004) Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 13(4):274–8CrossRefPubMed Sayarlioglu M, Inanc M, Kamali S et al (2004) Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 13(4):274–8CrossRefPubMed
6.
go back to reference Raviglione MC, O’Brien RJ (2012) Tuberculosis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) Harrison’s principle of internal medicine, vol I, 18th edn. McGraw Hill, New York, pp 1340–59 Raviglione MC, O’Brien RJ (2012) Tuberculosis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) Harrison’s principle of internal medicine, vol I, 18th edn. McGraw Hill, New York, pp 1340–59
7.
go back to reference Ueki A, Isozaki Y, Tomokuni A, Hatayama T, Ueki H, Kusaka M et al (2002) Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol 129(3):556–61CrossRefPubMed Ueki A, Isozaki Y, Tomokuni A, Hatayama T, Ueki H, Kusaka M et al (2002) Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol 129(3):556–61CrossRefPubMed
8.
go back to reference Horwitz DA, Gray DJ (2007) The interaction of T cells with cells of the innate immune system and B cells in the pathogenesis of SLE. In: Wallace DJ, Hannahs B (eds) Dubois’ lupus erythematosus, 7th edn. Lippincott Williams & Wilkins, Philadelphia, pp 133–161 Horwitz DA, Gray DJ (2007) The interaction of T cells with cells of the innate immune system and B cells in the pathogenesis of SLE. In: Wallace DJ, Hannahs B (eds) Dubois’ lupus erythematosus, 7th edn. Lippincott Williams & Wilkins, Philadelphia, pp 133–161
9.
go back to reference Zandman-Goddard G, Shoenfeld Y (2004) SLE and infections. In: Shoenfeld Y, Rose NR (eds) Infection and autoimmunity. Elsevier, Amsterdam, pp 491–503CrossRef Zandman-Goddard G, Shoenfeld Y (2004) SLE and infections. In: Shoenfeld Y, Rose NR (eds) Infection and autoimmunity. Elsevier, Amsterdam, pp 491–503CrossRef
10.
go back to reference Gruber R, Lederer S, Bechtel U, Lob S, Riethmuller G, Feucht HE (1996) Increased antibody titers against mycobacterial heat-shock protein 65 in patients with vasculitis and arteriosclerosis. Int Arch Allergy Immunol 110:95–8CrossRefPubMed Gruber R, Lederer S, Bechtel U, Lob S, Riethmuller G, Feucht HE (1996) Increased antibody titers against mycobacterial heat-shock protein 65 in patients with vasculitis and arteriosclerosis. Int Arch Allergy Immunol 110:95–8CrossRefPubMed
11.
go back to reference WHO (2008) WHO report 2008: Global tuberculosis control—surveillance, planning, financing. WHO, Geneva WHO (2008) WHO report 2008: Global tuberculosis control—surveillance, planning, financing. WHO, Geneva
Metadata
Title
Exacerbation of latent lupus: is the culprit acid-fast bacilli or antitubercular therapy?
Authors
Harpreet Singh
Sucharita Ray
Maneet Kaur
Vikas Gupta
Harish Kumar
Paulomi Talapatra
Rekha Mathur
Suvrat Arya
Naveen Ghangas
Publication date
01-08-2013
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 8/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2250-2

Other articles of this Issue 8/2013

Clinical Rheumatology 8/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine